Citadel Advisors
KMTS

Citadel Advisors’s Kestra Medical Technologies KMTS Stock Holding History

Citadel Advisors’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$904K Buy
35,534
+21,591
+155% +$452K ﹤0.01% 8451
2026
Q1 		$278K Sell
13,943
-29,700
-68% -$700K ﹤0.01% 10648
2025
Q4 		$1.16M Buy
+43,643
New +$1.12M ﹤0.01% 7069
2025
Q3 		– Sell
-1,508,298
Closed -$25M – 14537
2025
Q2 		$25M Buy
1,508,298
+578,168
+62% +$12.6M ﹤0.01% 1892
2025
Q1 		$23.2M Buy
+930,130
New +$21.4M ﹤0.01% 1873

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Citadel Advisors's KMTS Position: Q2 2026 in Review

Citadel Advisors increased its Kestra Medical Technologies (KMTS) stake by 155% in Q2 2026, buying an estimated $452K and bringing the position to 35,534 shares worth $904K. The position accounts for ﹤0.01% of the portfolio, ranked #8451.

Citadel Advisors first reported a position in KMTS in Q1 2025 and has held it in 5 quarters since. The position peaked at $25M in Q2 2025. 108 funds tracked by Wall St. Rank hold KMTS as of Q2 2026.

  • Citadel Advisors held 35,534 shares of Kestra Medical Technologies worth $904K as of Q2 2026.
  • Citadel Advisors bought 21,591 Kestra Medical Technologies shares in Q2 2026, an estimated $452K.
  • Kestra Medical Technologies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8451 holding.
  • Citadel Advisors first reported a position in Kestra Medical Technologies in Q1 2025 and has held it in 5 quarters since.
  • Citadel Advisors's Kestra Medical Technologies position peaked at $25M in Q2 2025.
  • 108 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.